Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10040MR)

This product GTTS-WQ10040MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10040MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7478MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ9176MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ7261MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ5743MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9442MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ14109MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ15552MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ10556MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW